XKRX
229000
Market cap34mUSD
Sep 16, Last price
1,957.00KRW
Name
Gencurix Inc
Chart & performance
P/E
—
P/S
6.07
EPS
—
Div yield, %
—
Shrs. gr., 5y
18.02%
Rev. gr., 5y
36.86%
Revenues
7.55b
+47.03%
Net income
-7.39b
L+78.07%
CFO
-6.24b
L-12.96%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Key people
Vice President
Jeong Do Park
Vice President
Chung Yeol Choi
Assistant Managing Director · since 2023
Jae Hwan Jung
Internal Auditor · since 2023
Mi Ran Kang
Assistant Managing Director
Sang Rae Cho
Chief Executive Officer, Director · since 2011
Jin Gu Jung
Director · since 2025
Hyeon Wuk Park
Director
Internal Auditor, Non-Executive Director
Jae Hun Shin
Other Non-Executive Director · since 2023
Se Hyeon Ahn
Non-Executive Independent Director · since 2025
Jun Seok Choi
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||